Scienture Holdings Inc

Research Scienture Holdings Inc (SCNX) on Bullrun: market cap USD 16.78M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 16.78M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 431.61K-USD 41.51M-USD 13.38M76.8%-2.7USD 6.66MUSD 24.14KUSD 70.12M
FY2024USD 136.64KUSD 9.07M-USD 14.28M4.4%2.48USD 308.10KUSD 2.90MUSD 79.07M
FY2023USD 1.36M-USD 17.84Mn/a3.6%-23.35USD 361USD 209.50KUSD 542.35K
FY2022USD 10.25M-USD 3.47Mn/a53.8%-6.13USD 1.09Mn/aUSD 763.14K

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 16.78Mn/an/an/a
20252025-12-31USD 20.72Mn/an/an/a
20242024-12-31USD 52.94Mn/a157.0%9.5
20232023-12-29USD 4.26Mn/an/an/a
20222022-12-30USD 3.76Mn/an/an/a
20212021-12-31USD 19.27Mn/an/an/a

Dividend history

YearDividends/share
FY20249.5 USD

About Scienture Holdings Inc

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Scienture Holdings Inc's market cap?

Scienture Holdings Inc's market capitalization is USD 16.78M.

What does Scienture Holdings Inc do?

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.